Kinnari Patel Net Worth

The estimated Net Worth of Kinnari Patel is at least $11.6 Million dollars as of 16 August 2024. Kinnari Patel owns over 3,989 units of Rocket Pharmaceuticals Inc stock worth over $7,554,586 and over the last 6 years he sold RCKT stock worth over $1,289,466. In addition, he makes $2,776,210 as Chief Operating Officer and Head of Development at Rocket Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Kinnari Patel RCKT stock SEC Form 4 insiders trading

Kinnari has made over 15 trades of the Rocket Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,989 units of RCKT stock worth $73,797 on 16 August 2024.

The largest trade he's ever made was exercising 93,962 units of Rocket Pharmaceuticals Inc stock on 24 March 2021 worth over $131,547. On average, Kinnari trades about 9,531 units every 83 days since 2018. As of 16 August 2024 he still owns at least 396,983 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Kinnari Patel stock trades at the bottom of the page.

Kinnari Patel biography

Dr. Kinnari Patel Pharm.D. serves as Chief Operating Officer and Head of Development of the Company. Dr. Patel joined us as Chief Operating Officer and Head of Development in January 2018 in connection with the Reverse Merger. Dr. Patel joined Private Rocket in April 2016, serving as Vice President – Head of Regulatory, Pharmacoviligence and Quality from April 2016 to July 2017 and as Senior Vice President, Global Program Head and Head of Regulatory and Quality from August 2017 to December 2017. Prior to joining Private Rocket, Dr. Patel was the Global Regulatory Lead at AstraZeneca from January 2015 to April 2016. Prior to that, Dr. Patel was Head of U.S. Risk Management at Bristol-Meyers Squibb from May 2014 through January 2015 and the U.S. Liaison for Global Regulatory Sciences at Bristol-Meyers Squibb from November 2010 to April 2014. Dr. Patel received the dual degrees of B.S. in Biology and Doctorate of Pharmacy from the USciences in Philadelphia, PA. She also completed a two-year Post-Doctoral Regulatory Affairs Fellowship through Rutgers University. Most recently, she received her Executive MBA from NYU Stern School of Business with specialization in Corporate Finance, Leadership and Strategy.

What is the salary of Kinnari Patel?

As the Chief Operating Officer and Head of Development of Rocket Pharmaceuticals Inc, the total compensation of Kinnari Patel at Rocket Pharmaceuticals Inc is $2,776,210. There are 1 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.

How old is Kinnari Patel?

Kinnari Patel is 41, he's been the Chief Operating Officer and Head of Development of Rocket Pharmaceuticals Inc since 2018. There are 16 older and no younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.

What's Kinnari Patel's mailing address?

Kinnari's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten, and Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.

What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Complete history of Kinnari Patel stock trades at Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gaurav Shah,
  President, Chief Executive Officer, Director
• Kinnari Patel,
  Chief Operating Officer and Head of Development
• Kamran Alam,
  Senior Vice President - Finance, Principal Financial Officer
• Jonathan Schwartz,
  Chief Medical Officer
• Dr. Gaurav D. Shah,
  CEO & Director
• Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
  Pres, COO & Head of Devel.
• Jonathan Schwartz,
  Chief Medical Officer & Sr. VP of Clinical Devel.
• John C. Militello CPA, CPA,
  VP, Sr. Controller & Principal Accounting Officer
• Roderick Wong,
  Chairman of the Board
• Pedro Granadillo,
  Independent Director
• Carsten Boess,
  Independent Director
• Naveen Yalamanchi,
  Independent Director
• Gotham Makker,
  Independent Director
• David Southwell,
  Director
• Elisabeth Bjork,
  Independent Director
• John Militello,
  Principal Accounting Officer and Senior Controller
• Dr. Gayatri R. Rao J.D., M.D.,
  Chief Devel. Officer of LVV & Sr. VP
• Isabel Carmona J.D.,
  Sr. VP & Chief HR Officer
• Kevin Giordano,
  Director of Corp. Communications
• Martin L. Wilson,
  Gen. Counsel, Chief Compliance Officer & Sr. VP
• Mayur Kasetty,
  Bus. Devel. & Operations and Investor Relations Lead
• Carlos Garcia-Parada M.B.A.,
  Chief Financial Officer
• Investments, Lpwong Roderic...,
  
• Mark Andrew White,
  See Remarks
• Investments, Lpwong Roderic...,
  
• Roderickrtw Investments, Lp...,
  
• Keith Woods,
  
• Fady Ibraham Malik,
  
• Carlos Garcia Parada,
  Chief Financial Officer
• Martin Wilson,
  General Counsel
• Mikael Dolsten,
  
• Aaron Ondrey,
  Chief Financial Officer